These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38109209)
1. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Wadhwa A; Wang S; Patiño-Escobar B; Bidkar AP; Bobba KN; Chan E; Meher N; Bidlingmaier S; Su Y; Dhrona S; Geng H; Sarin V; VanBrocklin HF; Wilson DM; He J; Zhang L; Steri V; Wong SW; Martin TG; Seo Y; Liu B; Wiita AP; Flavell RR Clin Cancer Res; 2024 Mar; 30(5):1009-1021. PubMed ID: 38109209 [TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy. Bidkar AP; Wang S; Bobba KN; Chan E; Bidlingmaier S; Egusa EA; Peter R; Ali U; Meher N; Wadhwa A; Dhrona S; Dasari C; Beckford-Vera D; Su Y; Tang R; Zhang L; He J; Wilson DM; Aggarwal R; VanBrocklin HF; Seo Y; Chou J; Liu B; Flavell RR Clin Cancer Res; 2023 May; 29(10):1916-1928. PubMed ID: 36917693 [TBL] [Abstract][Full Text] [Related]
4. Development of CD46 targeted alpha theranostics in prostate cancer using Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832 [No Abstract] [Full Text] [Related]
5. Preclinical Development of CD38-Targeted [ Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957 [No Abstract] [Full Text] [Related]
7. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma. Ma J; Zhang S; Yang N; Shang J; Gao X; Chen J; Wei H; Li Y; Zeng H; Xu H; Wang J; Liang SH; Wang R; Hu K; Wang L Eur J Nucl Med Mol Imaging; 2024 Sep; ():. PubMed ID: 39259226 [TBL] [Abstract][Full Text] [Related]
8. Development of [ Ghai A; Zheleznyak A; Mixdorf M; O'Neal J; Ritchey J; Rettig M; DiPersio J; Shokeen M; Achilefu S Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1302-1311. PubMed ID: 33179150 [TBL] [Abstract][Full Text] [Related]
9. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758 [TBL] [Abstract][Full Text] [Related]
10. A radiopharmaceutical [ Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708 [TBL] [Abstract][Full Text] [Related]
11. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416 [TBL] [Abstract][Full Text] [Related]
17. CD46 targeted Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664 [TBL] [Abstract][Full Text] [Related]
18. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals. Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491 [TBL] [Abstract][Full Text] [Related]
19. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Ruggiero A; Villa CH; Holland JP; Sprinkle SR; May C; Lewis JS; Scheinberg DA; McDevitt MR Int J Nanomedicine; 2010 Oct; 5():783-802. PubMed ID: 21042424 [TBL] [Abstract][Full Text] [Related]
20. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer. Parent EE; Gleba JJ; Knight JA; Kenderian SJ; Copland JA; Cai H Mol Imaging Biol; 2024 Oct; 26(5):847-857. PubMed ID: 39174789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]